Adaptive Biotechnologies (ADPT) Change in Accured Expenses (2018 - 2026)

Adaptive Biotechnologies has disclosed Change in Accured Expenses across 9 years of filings, most recently posting $1.0 million for Q2 2026.

• In Q2 2026, Change in Accured Expenses fell 69.1% year-over-year to $1.0 million; the TTM figure through Jun 2026 stood at $559000.0 (up 125.51% YoY), while the FY2025 annual figure was $665000.0, down 0.89% from the prior year.
• Change in Accured Expenses came in at $1.0 million for Q2 2026 at Adaptive Biotechnologies, up from -$7.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $10.5 million in Q4 2022 to a low of -$15.9 million in Q1 2023.
• Average Change in Accured Expenses over 5 years is -$192333.3, with a median of $708500.0 recorded in 2024.
• Year-over-year, Change in Accured Expenses tumbled 150.71% in 2023 and jumped 10093.22% in 2025.
• Over 5 years, Change in Accured Expenses stood at $10.5 million in 2022, then sank by 49.3% to $5.3 million in 2023, then slipped by 20.13% to $4.3 million in 2024, then plunged by 72.68% to $1.2 million in 2025, then dropped by 13.3% to $1.0 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $1.0 million in Q2 2026, -$7.5 million in Q1 2026, and $1.2 million in Q4 2025.